- Home
- SGHT vs STRO Comparison
SGHT vs STRO Comparison
Compare SGHT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGHT | STRO |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.9M | 85.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGHT | STRO |
|---|---|---|
| Price | $3.61 | $24.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | $9.08 | ★ $18.88 |
| AVG Volume (30 Days) | ★ 362.9K | 123.2K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,363,000.00 | N/A |
| Revenue This Year | $13.54 | $63.08 |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.03 | $0.52 |
| 52 Week High | $9.24 | $27.96 |
Technical Indicators
Market Signals| Indicator | SGHT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 28.52 | 68.81 |
| Support Level | $3.26 | $0.76 |
| Resistance Level | $3.70 | N/A |
| Average True Range (ATR) | 0.34 | 2.02 |
| MACD | -0.11 | 0.30 |
| Stochastic Oscillator | 1.20 | 64.40 |
Price Performance
Historical ComparisonAbout SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.